Want to join the conversation?
$VRTX 2Q15 Call: Global sales of KALYDECO this quarter were $155MM, comprised of US sales of approx. $93MM and ex-US sales of approx. $62MM. The company has seen good uptake in patients with R117H mutation following approval in US in late 2014, and in children ages 2-5 with eligible mutations following US approval at the end of March 2015.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.